| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.10. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 23.10.2025 | 641 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 23.10.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 23.10.2025.ISIN NameCA33564P1036 FIRST... ► Artikel lesen | |
| 23.10. | XFRA CAPITAL ADJUSTMENT INFORMATION - 23.10.2025 | 213 | Xetra Newsboard | Das Instrument 1AU FR0012789667 AMPLITUDE SURGIC. EO -,01 EQUITY wird cum Kapitalmassnahme gehandelt am 23.10.2025 und ex Kapitalmassnahme am 24.10.2025 The instrument 1AU FR0012789667 AMPLITUDE SURGIC.... ► Artikel lesen | |
| 13.10. | Amplitude Surgical SA: Results of the Simplified Tender Offer | 208 | Business Wire | Regulatory News:
Amplitude Surgical (ISIN: FR0012789667, Ticker: AMPLI, eligible for PEA-PME), the French leader in surgical technologies for lower limb orthopedics.
On 10 October 2025, the... ► Artikel lesen | |
| 10.10. | XFRA 1AU: AUSSETZUNG/SUSPENSION | 250 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILAMPLITUDE SURGIC.... ► Artikel lesen | |
| AMPLITUDE SURGICAL Aktie jetzt für 0€ handeln | |||||
| 30.07. | XFRA 1AU: WIEDERAUFNAHME/RESUMPTION | 148 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 29.07. | Zydus Announces Completion of the Acquisition of an 85.6% Stake in Amplitude Surgical and Upcoming Filing of a Simplified Tender Offer | 374 | Business Wire | Regulatory News:
Zydus Lifesciences Limited1 ("Zydus"), on March 11, 2025, entered into agreements with PAI and two minority shareholders of Amplitude Surgical (Paris:AMPLI) to acquire blocks of... ► Artikel lesen | |
| 29.07. | XFRA 1AU: AUSSETZUNG/SUSPENSION | 203 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILAMPLITUDE SURGIC.... ► Artikel lesen | |
| 29.07. | Amplitude Surgical - Suspension of Listing | 389 | Business Wire | Regulatory News:
Amplitude Surgical company has requested Euronext to suspend the listing of its shares (ISIN: FR0012789667, Ticker: AMPLI, eligible PEA-PME) on Euronext market with effect as from... ► Artikel lesen | |
| 24.07. | Amplitude Surgical - Consolidated annual revenue of €110.8 million, up +5.7% at constant exchange rates | 284 | Business Wire | Business growth of +3.8% at constant exchange rates in the fourth quarter of the 2024-25 financial year and of +5.7% for the full year
Strong momentum in France: revenue up +4.8%
Solid... ► Artikel lesen | |
| 25.04. | Zydus Lifesciences Limited Signs Purchase Agreement with PAI Partners and Other Shareholders to Acquire a Majority Stake in Amplitude Surgical SA | 398 | Business Wire | Regulatory News:
Amplitude Surgical SA (Paris:AMPLI):
Following the joint announcement of March 11, 2025, Zydus Lifesciences Limited ("Zydus") and Amplitude Surgical SA (Paris:AMPLI) ("Amplitude")... ► Artikel lesen | |
| 17.04. | Amplitude Surgical - 9-Months Consolidated Sales for FY 2024-25 of €83.8m, up +6.4% at Constant Exchange Rates | 333 | Business Wire | Sales up +6.6% at constant exchange rates in Q3 FY 2024-25
Consolidated sales for 9 months up+ 6.4% at constant exchange rates to €83.8m
Good momentum in France: sales up +4.7% over... ► Artikel lesen | |
| 17.04. | Zydus Lifesciences Limited announces the execution of undertakings to tender as part of its envisaged tender offer for Amplitude Surgical SA shares | 323 | PR Newswire | AHMEDABAD, India and PARIS, April 17, 2025 /PRNewswire/ -- Following the announcement of its envisaged tender offer on March 11, 2025, Zydus Lifesciences Limited announces the execution of... ► Artikel lesen | |
| 17.04. | Amplitude Surgical Has Been Informed by Zydus Lifesciences Limited of the Execution of Undertakings to Tender as Part of Its Envisaged Tender Offer for Amplitude Surgical SA Shares | 287 | Business Wire | Regulatory News:
Amplitude Surgical (ISIN: FR0012789667, Mnemo: AMPLI, PEA-PME eligible).
Following the announcement of the envisaged tender offer on March 11, 2025 of Zydus Lifesciences Limited... ► Artikel lesen | |
| 26.03. | Amplitude Surgical Announces H1 2024-25 Results: 51.5 M€ Sales and 13.1 M€ EBITDA | 452 | Business Wire | Consolidated sales of €51.5m, up 6.3% at constant exchange rates
EBITDA up 10.6% to €13.1 million, EBITDA margin 25.4%
Current operating income of €6.0 million
Cash position... ► Artikel lesen | |
| 12.03. | XFRA 1AU: WIEDERAUFNAHME/RESUMPTION | 264 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 11.03. | XFRA 1AU: AUSSETZUNG/SUSPENSION | 249 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILAMPLITUDE SURGIC.... ► Artikel lesen | |
| 11.03. | Zydus Enters Exclusive Negotiations with PAI Partners and Other Shareholders to Acquire a Majority stake in Amplitude Surgical, France | 426 | Business Wire | Completion of the transaction to be followed by mandatory simplified tender offer
Zydus has entered into exclusive negotiations to acquire a controlling shareholding in Amplitude Surgical,... ► Artikel lesen | |
| 20.02. | Amplitude Surgical - 1st Half-year 2024-25: Consolidated Sales of €51.5m, +6.3% at Constant Exchange Rates | 358 | Business Wire | Consolidated sales of €51.5 million, up+ 6.3% at constant exchange rates
Good sales growth in France at +4.6%
Strong growth in international business thanks to subsidiaries, with... ► Artikel lesen | |
| 21.11.24 | Amplitude Surgical - First Quarter 2024-25: Consolidated Sales of €21.8m, +7.5% at Constant Exchange Rates | 612 | Business Wire | VALENCE, France--(BUSINESS WIRE)--Regulatory News:
Amplitude Surgical (ISIN: FR0012789667, Mnemo: AMPLI, PEA-PME eligible), the French market leader in surgical technologies for lower limb orthopedics... ► Artikel lesen | |
| 20.11.24 | Amplitude Surgical Announces Its 2024-25 Financial Calendar | 150 | Business Wire | Regulatory News:
Amplitude Surgical (ISIN: FR0012789667, Mnemo: AMPLI, PEA-PME eligible), the French market leader in surgical technologies for lower limb orthopedics, announces its financial agenda... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ORGANON | 5,954 | +1,88 % | Jim Cramer's "Worst Stock Ever" Might Be Organon (OGN) | ||
| FRESENIUS | 49,510 | -1,02 % | DEUTSCHE BANK RESEARCH stuft Fresenius SE auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Fresenius von 52 auf 53 Euro angehoben und die Einstufung auf "Buy" belassen. Die anstehenden Quartalszahlen des Medizinkonzerns... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 48,740 | +0,35 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 16,870 | 0,00 % | Alignment Healthcare Reports Third Quarter 2025 Results, Surpasses High-End of Guidance Across All Key Metrics | Reports Q3 revenue of $993.7 million, up 43.5% year-over-yearBeats high end of third quarter guidance and raises full-year outlook across all key metrics: membership, revenue, adjusted gross profit... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 46,430 | -0,28 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 33,040 | 0,00 % | BrightSpring Health Services GAAP EPS of $0.17 misses by $0.15, revenue of $3.33B misses by $20M | ||
| GERRESHEIMER | 27,340 | -0,94 % | Gerresheimer: Weitere Details - millionenschwere Fehlbuchung | Am Wochenende hat der Spezialverpackungshersteller Gerresheimer per Ad-Hoc-Mitteilung dem Kapitalmarkt weitere Details zur laufenden Prüfung problematischer Buchungen im Konzernbericht für das Fiskaljahr... ► Artikel lesen | |
| UNITEDHEALTH | 296,00 | +0,61 % | Earnings Preview - Teil 1: Make or Break für den Markt: Die Zahlen von UnitedHealth, Microsoft & Alphabet! | © Foto: Richard Drew/AP/dpaDiese in den kommenden Tagen (KW44) anstehenden US-Quartalszahlen müssen Anlegerinnen und Anleger kennen: Herausforderungen, Erwartungen und die aktuell eingepreisten Kursreaktionen... ► Artikel lesen | |
| GENEDX | 137,17 | +4,20 % | GeneDx raises 2025 revenue guidance to $428M amid accelerating exome and genome test growth | ||
| BUTTERFLY NETWORK | 2,695 | 0,00 % | Butterfly Network reaffirms $91M-$95M 2025 revenue target while accelerating AI and chip innovation | ||
| PROCEPT BIOROBOTICS | 34,040 | 0,00 % | PROCEPT BioRobotics Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance | SAN JOSE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 44,060 | +0,36 % | JPMORGAN stuft CARL ZEISS MEDITEC AG auf 'Underweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat Carl Zeiss Meditec mit einem Kursziel von 35,10 Euro auf "Underweight" belassen. Vor den am 11. Dezember anstehenden Quartalszahlen lägen seine... ► Artikel lesen | |
| BETA BIONICS | 27,210 | 0,00 % | Beta Bionics, Inc.: Beta Bionics Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Guidance | IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial... ► Artikel lesen | |
| PROGYNY | 18,690 | 0,00 % | Progyny, Inc.: Progyny Expands Global Benefits to Include Pregnancy, Postpartum, and Menopause | Global employers can now empower their workforces with comprehensive women's health benefits, supported by localized expertiseNEW YORK, Oct. 22, 2025. (Nasdaq: PGNY), a global leader in women's health... ► Artikel lesen | |
| CLEARPOINT NEURO | 23,230 | 0,00 % | ClearPoint Neuro, Inc.: ClearPoint Neuro Announces Promising Results from Brain Tumor Laser Therapy Study to be Presented at the CNS Annual Meeting in Los Angeles | SOLANA BEACH, CALIFORNIA / ACCESS Newswire / October 7, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation... ► Artikel lesen |